Collegium Pharmaceutical (NASDAQ:COLL) CFO Sells $1,215,900.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the transaction, the chief financial officer owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This represents a 19.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Collegium Pharmaceutical Stock Up 4.0%

COLL stock traded up $1.64 during midday trading on Friday, hitting $42.30. 864,974 shares of the company’s stock were exchanged, compared to its average volume of 380,249. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of 40.67 and a beta of 0.61. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $43.06. The firm has a 50 day moving average price of $35.63 and a 200-day moving average price of $32.65.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The firm had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a net margin of 5.13% and a return on equity of 97.28%. On average, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Ratings Changes

COLL has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Truist Financial increased their price objective on Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.25.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of COLL. Federated Hermes Inc. lifted its stake in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the period. CWM LLC grew its position in shares of Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,153 shares during the period. Hantz Financial Services Inc. grew its holdings in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the period. Wealthquest Corp acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $62,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.